Ontology highlight
ABSTRACT:
SUBMITTER: Znati S
PROVIDER: S-EPMC7408860 | biostudies-literature | 2020 Jul
REPOSITORIES: biostudies-literature
Znati Sami S Carter Rebecca R Vasquez Marcos M Westhorpe Adam A Shahbakhti Hassan H Prince Jessica J Vlckova Petra P De Vellis Chiara C Bascal Zainab Z Loizidou Marilena M Sharma Ricky A RA
Cancers 20200713 7
Hepatocellular Carcinoma (HCC) is increasing in incidence worldwide and requires new approaches to therapy. The combination of anti-angiogenic drug therapy and radiotherapy is one promising new approach. The anti-angiogenic drug vandetanib is a tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) and RET proto-oncogene with radio-enhancement potential. To explore the benefit of combined vandetanib and radiotherapy treatment for HCC, we studied outcomes following c ...[more]